The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adjuvant chemotherapy for resected intrahepatic cholangiocarcinoma confers no survival advantage.
 
Jeremy Sharib
Stock and Other Ownership Interests - Intellia Therapeutics; Intuitive Surgical
Consulting or Advisory Role - Asensus Surgical
 
Annie Liu
No Relationships to Disclose
 
Sarah Margaret Helena McIntyre
No Relationships to Disclose
 
Kristen Elizabeth Rhodin
No Relationships to Disclose
 
Nancy E. Kemeny
Research Funding - Amgen
 
Andrea Cercek
Consulting or Advisory Role - Bayer; G1 Therapeutics; GlaxoSmithKline; Incyte; Janssen; Merck; Seagen
Research Funding - GlaxoSmithKline; Rgenix (Inst); Seagen
 
James J. Harding
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; Elevar Therapeutics; Exelixis; Hepion Pharmaceuticals; Imvax; Lilly; Medivir; Merck; QED Therapeutics; Zymeworks
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Codiak Biosciences (Inst); Debiopharm Group (Inst); Genoscience Pharma (Inst); Genoscience Pharma (Inst); Incyte (Inst); Lilly (Inst); Loxo (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); Yiviva (Inst); Zymeworks (Inst)
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Adicet Bio; Alnylam; AstraZeneca; Autem Medical; BeiGene; Berry Genomics; Celgene (I); Center for Emerging & Neglected Diseases (CEND) (I); CytomX Therapeutics (I); Eisai; Exelixis; Flatiron Health; Genoscience Pharma; Helio Health; Incyte; Ipsen; Lilly (I); Merck Serono; Nerviano Medical Sciences; QED Therapeutics; Rafael Pharmaceuticals (I); RedHill Biopharma; Roche/Genentech; SERVIER; Silenseed (I); SOBI (I); Vector Health; Yiviva; Yiviva
Research Funding - Agios (Inst); Arcus Ventures (Inst); AstraZeneca (Inst); Bayer (Inst); BioNtech (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Flatiron Health (Inst); Genentech/Roche (Inst); Genoscience Pharma (Inst); Incyte (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Silenseed (Inst); Yiviva (Inst)
Travel, Accommodations, Expenses - Polaris
 
Kevin Soares
No Relationships to Disclose
 
Alice Chia-chi Wei
Honoraria - AstraZeneca Canada; Medtronic
Consulting or Advisory Role - Biosapien; Histosonics
 
Jeffrey A. Drebin
Employment - American Regent (I)
Leadership - American Regent (I)
Stock and Other Ownership Interests - Alnylam; Arrowhead Pharmaceuticals; Ions Pharmaceuticals
 
T. Peter Kingham
Honoraria - Olympus Medical Systems
Consulting or Advisory Role - Physicans' Education Resource
 
Michael Ian D'Angelica
No Relationships to Disclose
 
Hope Elizabeth Uronis
Employment - GeneCentric (I)
Stock and Other Ownership Interests - GeneCentric (I)
Consulting or Advisory Role - AstraZeneca
Research Funding - Adaptimmune; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Leap Therapeutics (Inst); Macrogenics (Inst); Merck (Inst)
 
John H Strickler
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; GlaxoSmithKline; Inivata; Mereo Biopharma; Natera (Inst); Pfizer; Pionyr; Roche/Genentech (Inst); Seagen; Silverback Therapeutics; Takeda; Viatris; Zentalis
Research Funding - A*STAR (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Curegenix (Inst); Daiichi Sankyo/Lilly; Erasca, Inc (Inst); Leap Therapeutics (Inst); Nektar (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
Travel, Accommodations, Expenses - Guardant Health; Seagen
 
Michael Morse
Honoraria - AstraZeneca/Daiichi Sankyo; Bayer; Boehringer Ingelheim; Eisai; Exelixis; Genentech/Roche; Ipsen; Lexicon; Merck; Novartis; QED Therapeutics; Sanofi; SERVIER; Taiho Pharmaceutical; Tersera
Speakers' Bureau - Eisai; Exelixis; Genentech/Roche; Ipsen; SERVIER; Taiho Pharmaceutical
Research Funding - Advanced Accelerator Applications (Inst); AlphaVax (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lexicon (Inst); MedImmune (Inst); Merck (Inst); Onyx (Inst); Precision Biologics (Inst)
Patents, Royalties, Other Intellectual Property - Compositions And Methods For Modulating And Redirecting Immune Responses Publication number: 20170015758 Inventors: Scott A. HAMMOND, Michael A. MORSE, Takuya OSADA, Herbert Kim LYERLY; PHARMACEUTICAL PRODUCT, MEDICAL FOOD OR DIETARY SUPPLEMENT FOR PREVENTING CANCER AND INFLAMMATORY DISEASES Publication number: 20170246136 Applicant: OliVentures, Inc. Inventors: Carlos María Peña Díaz, Guillermo Muñoz Fernández, Michael Morse; Vaccines against antigens involved in therapy resistance and methods of using same Patent number: 9956276 Assignee Duke University
 
Sabino Zani
No Relationships to Disclose
 
Peter J Allen
Consulting or Advisory Role - Sanofi
Research Funding - Novartis
 
William R. Jarnagin
No Relationships to Disclose
 
Michael Lidsky
No Relationships to Disclose